Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 12, 2000, Pages 3402-3407

  Fu, L ^a   Cheng, Y C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CLEVUDINE; ELVUCITABINE; HEPATITIS B ANTIGEN; LAMIVUDINE; LEUCINE; METHIONINE; NUCLEOSIDE DERIVATIVE; PENCICLOVIR; QYL 685; UNCLASSIFIED DRUG; VALINE; VIRUS DNA; VIRUS RNA;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DNA REPLICATION; DRUG SCREENING; EVALUATION; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RNA TRANSCRIPTION; VIRAL GENETICS; VIRION; VIRUS RESISTANCE;

ACYCLOVIR; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, MICROBIAL; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; MICROBIAL SENSITIVITY TESTS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0034423384     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.12.3402-3407.2000     Document Type: Article

References (42)

1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
2. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
3. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy
4. Perspectives for the treatment of hepatitis B virus infections
5. A preliminary trial of lamivudine for chronic viral hepatitis B infection
6. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
7. A semiautomated microculture method for investigating exponentially growing carcinoma cells
8. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
9. Sensitivity of L-(-)2′3′-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
10. Regulation of hepatitis B virus gene expression by its enhancers
11. Regulation of hepatitis B virus gene expression by core promoter and its upstream sequences
12. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
13. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection
14. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine
15. Therapy of viral hepatitis
16. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
17. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay
18. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-α A inhibit replication of zidovudine-resistant human immunodeficiency virus type I synergistically in vitro
19. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells
20. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues
21. Treatment of chronic hepatitis B virus infection: An Asia-Pacific perspective
22. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-βL-cytidine (β-L(-)d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β-L-5- fluorocytidine(β-L(-)Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro
23. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus
24. Antiviral chemotherapy for chronic hepatitis B infection: Lesions learned from treating HIV-infected patients
25. Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance
26. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
27. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences
28. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
29. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
30. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir
31. Inhibition of hepatitis B virus by a novel L-nucleotide, 2′-fluoro-5-methyl-β-L-arabinofuranosyl uracil
32. Update on clinical trails in the treatment of hepatitis B
33. Antivial drug resistance: From the laboratory to the patient
34. Synthesis and antiviral activity of phosphoralinate derivatives of methylenecyclopropane analogues of nucleosides
35. Cell-based and animal models for hepatitis B and C viruses
36. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
37. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatits B virus DNA
38. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
39. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
40. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
41. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro